Saudi Arabia Genomics Market: Precision Medicine, DNA Sequencing & Growth Outlook

According to IMARC Group's latest research publication, Saudi Arabia genomics market size reached USD 229.8 Million in 2025. The market is projected to reach USD 616.5 Million by 2034, exhibiting a growth rate (CAGR) of 11.59% during 2026-2034.

How AI is Reshaping the Future of Saudi Arabia Genomics Market

• Accelerated Genome Sequencing Analysis: AI-powered bioinformatics pipelines at Genalive's Riyadh facility process 1,000 genomes monthly, with scaling planned to 5,000 monthly, reducing variant interpretation time from days to hours while identifying pathogenic mutations with 35% greater accuracy.
• Predictive Disease Risk Modeling: Machine learning algorithms analyze genetic variants alongside clinical and environmental data, enabling early identification of high-risk individuals for chronic conditions like diabetes and cardiovascular diseases, which now constitute the majority of Saudi Arabia's disease burden.
• Personalized Treatment Optimization: AI integrates clinical, genomic, and behavioral data to tailor medical interventions based on individual genetic profiles, moving the Kingdom closer to precision medicine goals under Vision 2030's Health Sector Transformation Program with over 3,000 jobs created in bioinformatics.

How Vision 2030 is Revolutionizing Saudi Arabia Genomics Industry

Vision 2030 has positioned genomics as a cornerstone of Saudi Arabia's healthcare transformation strategy, channeling over SAR 50 billion (USD 13.33 billion) into healthcare innovation infrastructure. The flagship Saudi Human Genome Program, inaugurated by Crown Prince Mohammed bin Salman in 2018 and managed by King Abdulaziz City for Science and Technology, targets sequencing 100,000 Saudi genomes—achieving 63,000 sequenced genomes representing 63% completion—to build a comprehensive national genetic database addressing the Kingdom's high prevalence of hereditary diseases affecting 8% of births and 20% of the population due to 56% consanguinity rates. BGI Genomics secured a landmark three-year NUPCO contract providing 930,000 genetic testing services across 83 public hospitals, including whole genome sequencing, whole exome sequencing, and hereditary cancer screening.

Download the Sample Report to Understand Market Trends and Outlook

Market Trends & Drivers:

National Genomics Infrastructure Driving Localized Capacity

Saudi Arabia's genomics market is experiencing rapid expansion powered by strategic government investments in building sovereign genomic capabilities and reducing reliance on international laboratories. The establishment of Genalive in 2023—a 4,000-square-meter advanced clinical genomics laboratory in Riyadh developed through BGI Genomics' partnership with Tibbiyah Holding—represents one of the region's most sophisticated facilities, housing high-throughput sequencing platforms and one of the Middle East's largest healthcare data centers. Eight genomic laboratories now operate nationwide providing accessible testing services, while the Saudi-German Genomic Centre delivers comprehensive diagnostic services across the GCC using next-generation sequencing technologies.

Addressing High Genetic Disease Burden Through Population-Specific Research

Saudi Arabia faces unique public health challenges stemming from high consanguineous marriage rates, creating urgent demand for genomic solutions tailored to the Kingdom's population. With a 56% consanguinity rate among the world's highest the prevalence of genetic disorders including beta-thalassemia, sickle cell anemia, and various metabolic diseases creates significant strain on the healthcare system. Hereditary conditions affect approximately 8% of births and 20% of the overall population, driving substantial healthcare expenditures and reducing quality of life for affected families. The Saudi Genome Program directly addresses these challenges by mapping genetic variants specific to Saudi citizens, having identified 3,000 novel mutations causing 1,230 rare genetic disorders and developed 25 gene panels for targeted screening.

Next-Generation Sequencing Adoption and Cost Reduction Accelerating Access

Technological advancements in DNA sequencing, particularly next-generation sequencing adoption, are fundamentally reshaping genomics market dynamics by making comprehensive genetic testing economically viable at population scale. Whole-genome sequencing costs plummeted 60% since the Saudi Genome Program's inception, declining from historical levels exceeding USD 100,000 to approximately USD 1,000 per genome, with projections suggesting further reductions enabling mass screening initiatives. This dramatic cost compression democratizes access to genetic testing, facilitating early diagnosis and personalized treatment plans across socioeconomic strata rather than limiting advanced genomics to elite medical centers or wealthy patients.

Saudi Arabia Genomics Market Industry Segmentation:

The report has segmented the market into the following categories:

Component Insights:

• Products
• Instruments and Software
• Consumables and Reagents
• Services
• Core Genomics Services
• NGS-Based Services
• Biomarker Translation Services
• Computational Services
• Others

Application Insights:

• Functional Genomics
• Epigenomics
• Biomarkers Discovery
• Pathway Analysis
• Others

Technology Insights:

• Sequencing
• Microarray
• Polymerase Chain Reaction
• Nucleic Acid Extraction and Purification
• Others

End User Insights:

• Research Centers
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Others

Regional Insights:

• Northern and Central Region
• Western Region
• Eastern Region
• Southern Region

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Recent News and Developments in Saudi Arabia Genomics Market

• September 2025: BGI Genomics unveiled "i99", an AI-powered health management platform integrating genomic, epigenetic, microbiome, imaging, and lifestyle data to generate actionable insights for disease prevention and long-term health planning aligned with Saudi Vision 2030.
• January 2025: Genalive was awarded a three-year contract by the National Unified Procurement Company (NUPCO) under the Saudi Ministry of Health, providing over 930,000 genetic testing services across 83 public hospitals throughout the Kingdom.
• November 2024: Ministry of Investment (MISA) partnered with Novartis to strengthen Saudi Arabia's biopharmaceutical capabilities through local investments in cell and gene therapy, technology transfer, and clinical research, contributing approximately USD 857 million to GDP.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.